4D pharma plc
FOUR.LShift4 Payments, Inc. is an American payment processing company based in Allentown, Pennsylvania. The company, founded in 1999 by the then 16-year-old Jared Isaacman, processes payments for over 200,000 businesses in the retail, hospitality, leisure, and restaurant industries. Shift4 specializes in commerce technology such as mobile payment software and hardware. The company was publicly listed on the New York Stock Exchange in 2020.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Blautix | Phase 2 | Irritable Bowel Syndrome | - | - |
Frequently asked questions
What is in 4D pharma plc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in 4D pharma plc's (FOUR.L) pipeline across Phase 2. Its lead program is Blautix (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is 4D pharma plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for 4D pharma plc (FOUR.L) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FOUR.L biotech catalysts?→
Add FOUR.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow 4D pharma plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.